Deutsche Bank analyst Pito Chickering raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $160 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
- Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating
- Quest Diagnostics Reports Strong Q2 2025 Results
- Quest Diagnostics Reports Strong Growth in Earnings Call
- Morning Movers: Lockheed Martin slips following second quarter report